| Domestic Pharmaceutical Market - India | Wide range of formulations including gynecology, cardiovascular, anti-infectives, chronic therapies, consumer health products. | Strong brand presence, deep market penetration, robust R&D for differentiated products. | Hospitals, clinics, pharmacies, consumers across India. | Branded formulations and novel drug delivery system products. | 3659 | 46 | Sales through pharmacies, hospitals, and distributors under B2B and B2C models. | Traditional sales with strategic pricing and brand positioning. | Expansion in chronic and acute therapies, new product launches, enhanced marketing and in-licensing partnerships. | Elaxim, Tenectase, Hamsyl, Arth |
| International Markets - Europe | Generic injectables, complex biosimilars, specialty pharmaceuticals. | Exclusive portfolios, regulatory approvals, strategic acquisitions enabling market entry and expansion. | Healthcare providers, government tenders, pharmacies in Europe. | Complex injectables and biosimilars. | 1525 | 19 | Product sales via distributors and tenders to hospitals and pharmacies. | Contract sales, tenders, long-term supply agreements. | Acquisition of Manx portfolio, product launches in injectables and biosimilars, market share gains. | Liposomal Amphotericin B, Manx portfolio, Ferric Carboxymaltose |
| International Markets - North America | Complex generics including injectables, biosimilars, antivirals. | Robust filing pipeline, patent challenges, niche regulatory expertise. | Hospitals, clinics, pharmacies, specialty providers in US and Canada. | ARV antivirals, oncology biosimilars. | 1297 | 16 | Sales via partnerships, distributor networks, and institutional clients. | Direct sales, supply contracts, reimbursement-based pricing. | Strong pipeline launches, growth in ARV and oncology products, first-to-market generics. | Multiple generic formulations across therapeutic areas |
| International Markets - Other Continents | Biosimilars, injectables, ARV products, novel drug delivery systems. | Global patents, first-to-market products, strategic geographic diversification. | Government health programs, private healthcare providers, pharmacies worldwide. | Biosimilars and complex injectables. | 1415 | 19 | Sales to hospitals, health ministries, and commercial channels. | Mixed models including tender, direct sales, and partnerships. | Expansion in emerging markets, biosimilar approvals, dermatology and consumer health launch. | Lenacapavir, Bevacizumab, Tenectaplase biosimilar |
